当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2012年第10期
编号:12200427
常见实验动物前列腺部尿道张力调控受体的差异性及其药理学意义(4)
http://www.100md.com 2012年4月5日 《中国医药导报》 2012年第10期
     [24] Mutoh S,Latifpour J,Saito M,et al. Evidence for the presence of regional differences in the subtype specificity of muscarinic receptors in rabbit lower urinary tract [J]. J Urol,1997,157(2):717-721.

    [25] Ekstrm J,Malmberg L. On a cholinergic motor innervation of the rat urethra [J]. Acta Physiol Scand,1984,120(2):237-242.

    [26] Chen HI. Evidence for the presynaptic action of 5-hydroxytryptamine and the involvement of purinergic innervation in the rabbit lower urinary tract [J]. Br J Pharmacol,1990,101(1):212-216.

    [27] Pinna C,Glass R,Knight GE,et al. Purine- and pyrimidine-induced responses and P2Y receptor characterization in the hamster proximal urethra [J]. Br J Pharmacol,2005,144(4):510-518.

    [28] Fibbi B,Morelli A,Vignozzi L,et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract [J]. J Sex Med,2010,7(1):59-69.

    [29] Tinel H,Stelte-Ludwig B,Hütter J,et al. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms [J]. BJU Int,2006,98(6):1259-1263.

    (收稿日期:2011-08-25 本文编辑:程 铭), 百拇医药(苏欣 吴建辉 孙祖越)
上一页1 2 3 4